764—3对大鼠实验性肺纤维化的保护作用  

Protective Effect of 764-3 on Experimental Lung Fibrosis in Rats

作　　者：陈祥银[1] 西品香[1] 严仪昭[1] 孙仁宇[1] 

机构地区：[1]中国医学科学院基础医学研究所

出　　处：《中国医学科学院学报》1992年第4期262-266,共5页Acta Academiae Medicinae Sinicae

摘　　要：给大鼠气管内一次滴注博莱霉素,观察肺部炎症及其修复形成肺纤维化的过程.滴注后第7、21天,可见肺系数及肺组胺含量显著升高。第21天时还有血清丙二醛含量显著升高,而此时肺羟脯氨酸含量无明显改变。提示为亚急性炎症阶段。第60天时,肺羟脯氨酸含量显著升高,表明有肺纤维化形成。764-3治疗可显著缓解博莱霉素所致的上述指标的变化。提示764-3可防止博莱霉素所致肺炎症及其随后发展成肺纤维化。这一作用除直接与其对抗早期的炎症过程有关外,尚不能排除直接地抗纤维化作用。Bleomycin was given to rats via a single intratracheal injection to investigate the development of lung inflammation and fibrosis. Increases in lung index and lung histamine content after 7 and 21 days and an increase of serum MDA content after 21 days were found. But there was no obvious change in lung hydroxyproline content. The results indicated that the acute and subacute inflammatory phases were induced by bleomycin over this period, Lung hy- droxyproline content significantly increased after 60 days, demonstrating the onset of fibrosis. 764-3 treatment could obviously attenuate the changes in the above mentioned parameters, suggesting that 764-3 can prevent the lung inflammation and ensuing fibrosis caused by bleomycin. Besides direct antiin-flammatory effects in the early phase, direct and indirect antifibrotic actions might also be part of the 764-3 protective effect.

关 键 词：博莱霉素 肺纤维化 组胺 

分 类 号：R965[医药卫生—药理学]